Lundbeck announced May 29 that its investigational compound LuAE58054 met its primary endpoint in a fixed dose, randomized, placebo-controlled study in 278 patients with Alzheimer’s disease. LuAE58054 is a novel, selective 5HT6 receptor antagonist. Augmentation therapy with LuAE58054 (plus 10 mg/day donepezil) at the selected dose resulted in statistically significant improvement in cognition, as measured by the Alzheimer’s Disease Assessment Scale-cognitive subscale over a 24-week treatment period versus placebo (plus 10 mg/day donepezil). Secondary endpoints, including measures of global status and activities of daily living, also showed positive trends with the addition of LuAE58054, compared with donepezil. The study was conducted in several European countries as well as Canada and Australia.